Quick Take
Constellation Pharmaceuticals (CNST) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is a clinical-stage biopharmaceutical company which uses epigenetics, a regulatory system that controls gene expression by modifying chromatin, to develop treatments for prostate and other cancers.
CNST’s candidates show promising Phase 1 trial results, the firm has a top tier institutional investor syndicate and management expects to report top line trial results in mid-2019.
Company & Technology
The Cambridge, Massachusetts-based pharmaceutical company was founded in 2008 to